Vicarious Surgical Inc. (RBOT)

Vicarious Surgical Inc. was a development-stage medical technology company based in Waltham, Massachusetts, working on a surgical robot. It was founded in 2014 and was led by co-founders Adam Sachs and Sammy Khalifa, with the goal of making minimally invasive surgery possible through a single small incision.

The company's technology, the Vicarious System, used two small robotic arms inserted through one incision and a camera, with the surgeon wearing a virtual reality headset and controlling the instruments with hand controllers. The design aimed to give the surgeon the sense of being inside the patient's body. The initial target procedure was ventral hernia repair, with other abdominal procedures described as future applications.

As a pre-commercial company, Vicarious Surgical did not generate meaningful revenue and relied on outside financing to fund research, engineering and clinical preparation. It received investment from prominent technology figures and venture investors before going public.

The company became public in September 2021 through a business combination with D8 Holdings Corp., a special purpose acquisition company, and its Class A common stock and warrants began trading on the New York Stock Exchange under the symbols RBOT and RBOTW. In later years the company reduced costs, restructured its workforce, and pursued additional funding while moving toward human clinical testing.

As the share price and market value declined, the company became vulnerable to the NYSE's continued listing standards. On March 3, 2026, Vicarious Surgical announced that the NYSE had determined that it fell below the standard requiring an average global market capitalization of at least $15 million over 30 consecutive trading days, under Section 802.01B of the NYSE Listed Company Manual. Trading on the NYSE was suspended after the close of that day.

The company said its shares would begin quotation on the OTCID tier of OTC Markets Group on March 4, 2026 under the same symbol, RBOT, and that it was evaluating whether to appeal the determination. The NYSE subsequently filed a Form 25 to remove the common stock and warrants from listing. No acquirer or successor company has been identified.

A company that falls below the NYSE market capitalization standard may be suspended immediately, with only a limited appeal right. After suspension, the securities typically move to an over-the-counter market, where liquidity and disclosure expectations differ from those on a national exchange. The Form 25 becomes effective ten days after filing, completing the formal delisting.